This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Glaukos (GKOS) delivered earnings and revenue surprises of 66.67% and 7.77%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Glaukos (GKOS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Glaukos (GKOS) Banks on Solid Pipeline Amid Stiff Competition
by Zacks Equity Research
Glaukos' (GKOS) strong pipeline is indicative of brighter prospects ahead. However, cutthroat competition in the medical-device industry is worrisome.
Earnings Preview: Glaukos (GKOS) Q4 Earnings Expected to Decline
by Zacks Equity Research
Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Glaukos (GKOS) delivered earnings and revenue surprises of -35.71% and 8.94%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Glaukos (GKOS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Glaukos (GKOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Glaukos (GKOS) Jumps: Stock Rises 7.2%
by Zacks Equity Research
Glaukos (GKOS) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Glaukos (GKOS) delivered earnings and revenue surprises of -15.38% and 5.85%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Is SPDR S&P Health Care Equipment ETF (XHE) a Hot ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XHE
Weakness Seen in Glaukos (GKOS) Estimates: Should You Stay Away?
by Zacks Equity Research
Glaukos (GKOS) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Cerner (CERN) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
Cerner Corp (CERN) reported adjusted first-quarter 2017 earnings of 56 cents per share, beating the Zacks Consensus Estimate of 53 cents.
CONMED (CNMD) Q1 Earnings Surpass Estimates, Increase Y/Y
by Zacks Equity Research
CONMED Corporation (CNMD) reported first-quarter 2017 adjusted earnings of 38 cents per share, beating the Zacks Consensus Estimate by 4 cents.
Stryker (SYK) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
Stryker Corp (SYK) reported adjusted earnings of $1.48 per share in the first quarter of 2017, which comfortably beat the Zacks Consensus Estimate by 5 cents.
DexCom (DXCM) Incurs Narrower Loss in Q4, Beats on Revenues
by Zacks Equity Research
DexCom Inc. (DXCM) reported loss of nine cents per share in the fourth quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of 10 cents.
The Cooper Companies (COO) Beats Earnings Estimates in Q1
by Zacks Equity Research
The Cooper Companies Inc.(COO) reported adjusted earnings of $1.93 in first-quarter fiscal 2017, surpassing the Zacks Consensus Estimate by 7 cents and improving 5.5% on a year-over-year basis.
NxStage Medical: NxGen Hemodialysis System Now CE Marked
by Zacks Equity Research
NxStage Medical, Inc. (NXTM) recently announced the receipt of CE mark for its NxGen Hemodialysis System, an innovative device with easier user interface and integrated blood pressure monitor system for patients performing home hemodialysis.
Amedisys Stock Up on Solid Earnings, Reimbursement Woes Stay
by Zacks Equity Research
On Mar 02, we issued an updated research report on renowned home health and hospice services provider Amedisys Inc. (AMED).
VWR Corp Poised on Strong Earnings Amid Currency Headwinds
by Zacks Equity Research
On Feb 28, we issued an updated research report on VWR Corporation (VWR), an independent worldwide provider of products, services and solutions to laboratory and production facilities.
Baxter Partners ScinoPharm, Expands in Generic Injectables
by Zacks Equity Research
Baxter International Inc. (BAX) has formed a strategic partnership with Taiwan-based process R&D and active pharmaceutical ingredient (API) manufacturer, ScinoPharm Taiwan, Ltd.
Hill-Rom Holdings Hits a 52-Week High on Solid Prospects
by Zacks Equity Research
Share price of Batesville, IN-based Hill-Rom Holdings, Inc.(HRC) scaled a new 52-week high of $67.44 on Mar 1, eventually closing a tad lower at $67.21.
Amedisys Buys 6 Home Health, Hospice Care Centers from Tenet
by Zacks Equity Research
Amedisys Inc. (AMED), a household name in home health and hospice services space, recently signed an exclusive agreement with Tenet Healthcare Corporation (THC).
Penumbra (PEN) Q4 Loss Narrower than Expected, Sales Top
by Zacks Equity Research
Penumbra, Inc. (PEN), that went public in Sep 2015, reported fourth-quarter 2016 loss of 8 cents per share, down from earnings of 5 cents per share year over year.
Inogen (INGN) Tops Earnings & Revenues in Q4; View Upbeat
by Zacks Equity Research
Inogen Inc. (INGN) reported fourth-quarter 2016 earnings of 25 cents per share, which surpassed both the Zacks Consensus Estimate by 15 cents and the year-ago figure by 11 cents.
Mead Johnson Acquires Bega's Strategic Capabilities Business
by Zacks Equity Research
Mead Johnson Nutrition Company (MJN) recently inked an agreement with Bega Cheese Limited to acquire the latter's spray drying and finishing capabilities business in Australia.
Varian (VAR): Calypso Tumor Tracking System Now in Brazil
by Zacks Equity Research
Varian Medical Systems, Inc. (VAR), recently announced that Moinhos de Vento Hospital has become the first cancer treatment center in Brazil with Varian's flagship product Calypso, a tumor tracking system for cancer treatment.